 |
|
Hazard-Rate Analysis in Stage I Malignant Melanoma
Gary S. Rogers, MD;
Alfred W. Kopf, MD;
Darrell S. Rigel, MD;
Robert J. Friedman, MD;
Marcia Levenstein, DSc;
Robert S. Bart, MD
Arch Dermatol. 1986;122(9):999-1002.
Abstract
• Hazard-rate analysis provides a unique means of assessing prognosis in patients with malignant disease. The hazard rate is the probability of a patient dying within a particular unit of time after definitive therapy. Hazardrate analysis was performed on a series of 719 consecutive patients with clinical stage I cutaneous malignant melanoma (MM). The peak hazard rate for death from metastatic MM occurred during the 48th month of followup. Thereafter, the hazard rate declined and approached zero by the 120th month. When the patients were stratified by the thickness of their primary MM, thicker lesions reached their peak hazard-rate month earlier than thinner lesions. We conclude that after 120-month survival, the risk of dying from MM is virtually zero. However, since rare late deaths from MM occur, lifetime follow-up is recommended.
(Arch Dermatol 1986;122:999-1002)
Author Affiliations
From the Department of Dermatology, New York University School of Medicine; the Oncology Section, Skin and Cancer Unit, University Hospital, New York; and the Melanoma Cooperative Group, New York University Medical Center.
Footnotes
Accepted for publication April 2, 1986.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Rational Follow-up Recommendations for Patients With Melanoma
Chartier and Bigby
Arch Dermatol 2000;136:1145-1148.
FULL TEXT
Total-Body Photographs of Dysplastic Nevi
Slue et al.
Arch Dermatol 1988;124:1239-1243.
ABSTRACT
Prognosis in Melanoma: What Have We Learned?
Koh
Arch Dermatol 1986;122:993-994.
ABSTRACT
|
